The Society for Immunotherapy of Cancer (SITC) hosted Session 207a during the 38th Annual Meeting & Pre-Conference Programs on Saturday, November 4, 2023. Available here are the presentation slides and video from “Session 207a: Immune Therapy Toxicities, Evolving Frontiers” as permitted by presenters.
Douglas Johnson, MD, MSCI – Vanderbilt University Medical Center
Bianca Santomasso, MD, PhD – Memorial Sloan Kettering Cancer Center
Immune checkpoint inhibitors and cellular therapies produce durable responses in a subset of treated patients, but also cause a diverse array of toxicities related to dysregulated immunity. In this session, we will discuss the emerging pathophysiology of these immune-related toxicities, from immune-related adverse events (irAEs) to the immune effector cell-associated toxicities of cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome. Dr. Nirali Shah will present an overview of the clinical features, grading, pathophysiology, and treatment approaches for the newly defined immune effector cell associated HLH-like syndrome (IEC-HS). Dr. Chloe Villani will present an overview of the systematic single-cell characterization of patients with irAEs done by her group, producing a variety of insights into the pathogenesis of irAEs. Finally, session chairs Drs. Bianca Santomasso and Douglas Johnson will synthesize current research and commonalities between CAR-T and immune checkpoint inhibitor associated toxicities.
To view the entire program schedule (including presenter permission to post) please click here.
SITC 2023 Annual Meeting: Saturday, November 401:32:04